Altered pathways and colorectal cancer prognosis

BMC Medicine

Rebeca Sanz-Pamplona¹  Victor Moreno² 

[1]Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL) and Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Barcelona, Spain

[2]Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain

关键词: Molecular subtypes;    Pathways;    Prognosis;    Colorectal cancer;   

Others  :  1160627
DOI  :  10.1186/s12916-015-0307-6

 received in 2015-03-02, accepted in 2015-03-02,  发布年份 2015

【 摘 要 】

The identification of molecular markers with prognostic value in colorectal cancer is a challenging task that is needed to define therapeutic guidelines. Clinical factors are insufficient to identify those patients with stage II at risk of relapse or those patients with stage III at low risk. There is a current effort to define a consensus in molecular subtypes based on expression profiles, which are characterized by a distinctive prognostic outcome. Also several gene expression signatures based on individual genes have been proposed to predict prognosis, but they show low consistency and reproducibility. Slattery et al. describe a pathway-based approach to analyze gene expression differences between normal and colon cancer tissues. The most interesting finding is that having more deregulated pathways is associated with good prognosis. If these findings are properly validated, new insights into the mechanisms of colon carcinogenesis may be revealed.

Please see related article: http://dx.doi.org/10.1186/s12916-015-0292-9 webcite.

【 授权许可】

   
2015 Moreno and Sanz-Pamplona; licensee BioMed Central.

【 参考文献 】

• [1]Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22:1797-806.
• [2]Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 6:479-507.
• [3]Sanz-Pamplona R, Santos C, Grasselli J, Molleví DG, Dienstmann R, Paré-Brunet L, et al.: Unsupervised analyses reveal molecular subtypes associated to prognosis and response to therapy in colorectal cancer. Colorectal Cancer 2014, 3:277-88.
• [4]Sadanandam A, Wang X, de Sousa EMF, Gray JW, Vermeulen L, Hanahan D, et al.: Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 2014, 13:353-7.
• [5]Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Sole X, Crous-Bou M, et al.: Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One 2012, 7:e48877.
• [6]Lascorz J, Chen B, Hemminki K, Forsti A: Consensus pathways implicated in prognosis of colorectal cancer identified through systematic enrichment analysis of gene expression profiling studies. PLoS One 2011, 6:e18867.
• [7]Slattery ML, Herrick JS, Mullany LE, Gertz J, Wolff RK. Improved survival among colon cancer patients with increased differentially expressed pathways. BMC Med. 2015. doi:10.1186/s12916-015-0292-9.
• [8]Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S, et al.: Signaling pathways activation profiles make better markers of cancer than expression of individual genes. Oncotarget 2014, 5:10198-205.
• [9]Huang S, Yee C, Ching T, Yu H, Garmire LX: A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. PLoS Comput Biol 2014, 10:e1003851.
• [10]Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, et al.: EMT is the dominant program in human colon cancer. BMC Med Genomics 2011, 4:9. BioMed Central Full Text
• [11]Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al.: Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014, 134:552-62.
• [12]Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al.: Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012, 5:66. BioMed Central Full Text
• [13]Lamouille S, Xu J, Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014, 15:178-96.
• [14]Miyazono K: Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009, 85:314-23.
• [15]Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R: Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol 2012, 21:316-23.
• [16]Sanz-Pamplona R, Berenguer A, Cordero D, Mollevi DG, Crous-Bou M, Sole X, et al.: Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer 2014, 13:46. BioMed Central Full Text
• [17]Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2015. doi:10.1038/ng.3224.
• [18]Cordero D, Sole X, Crous-Bou M, Sanz-Pamplona R, Pare-Brunet L, Guino E, et al.: Large differences in global transcriptional regulatory programs of normal and tumor colon cells. BMC Cancer 2014, 14:708. BioMed Central Full Text
• [19]Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–37.